231 related articles for article (PubMed ID: 33882697)
41. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
42. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
Mineiro Dos Santos Garrett NF; Carvalho da Costa AC; Barros Ferreira E; Damiani G; Diniz Dos Reis PE; Inocêncio Vasques C
PLoS One; 2021; 16(8):e0255716. PubMed ID: 34358260
[TBL] [Abstract][Full Text] [Related]
43. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
44. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment of immune checkpoint inhibitor-related periaortitis.
Bührer ED; Alberts IL; Christ L; Özdemir BC
Swiss Med Wkly; 2024 Feb; 154():3631. PubMed ID: 38579296
[TBL] [Abstract][Full Text] [Related]
46. External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition.
Glehr G; Riquelme P; Yang Zhou J; Cordero L; Schilling HL; Kapinsky M; Schlitt HJ; Geissler EK; Burkhardt R; Schmidt B; Haferkamp S; Hutchinson JA; Kronenberg K
Front Immunol; 2022; 13():1011040. PubMed ID: 36248910
[TBL] [Abstract][Full Text] [Related]
47. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
48. Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.
Kim S; Lahu G; Vakilynejad M; Soldatos TG; Jackson DB; Lesko LJ; Trame MN
Clin Transl Sci; 2022 Jun; 15(6):1430-1438. PubMed ID: 35191192
[TBL] [Abstract][Full Text] [Related]
49. Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort.
Ksienski D; Truong PT; Wai ES; Croteau NS; Chan A; Patterson T; Clarkson M; Hackett S; Irons S; Lesperance M
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e561-e569. PubMed ID: 34226113
[TBL] [Abstract][Full Text] [Related]
50. Immune checkpoint inhibitor-induced granulomatosis with polyangiitis.
Hung W; Cusnir I; Habib S; Smylie M; Solez K; Yacyshyn E
Rheumatology (Oxford); 2021 Jun; 60(6):e190-e191. PubMed ID: 33367837
[No Abstract] [Full Text] [Related]
51. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
Saiki R; Katayama K; Saiki H; Fukumori A; Tsujimoto K; Yamawaki M; Tanaka F; Takahashi D; Oda K; Suzuki Y; Murata T; Dohi K
BMC Nephrol; 2024 Feb; 25(1):51. PubMed ID: 38336610
[TBL] [Abstract][Full Text] [Related]
52. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
53. Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.
Yamamoto K; Oka K; Son R; Honda H; Sakae H; Hasegawa K; Horiguchi S; Kato H; Yamasaki O; Otsuka F
Mod Rheumatol Case Rep; 2021 Jul; 5(2):425-430. PubMed ID: 33821775
[TBL] [Abstract][Full Text] [Related]
54. Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first.
Storwick JA; Tam H; Rosenbaum DG; Houghton K
Pediatr Rheumatol Online J; 2024 Apr; 22(1):49. PubMed ID: 38685034
[TBL] [Abstract][Full Text] [Related]
55. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?
Hussain K; Kawsar A; Weir J; Au L; Turajlic S; Larkin J; Fearfield L
Clin Exp Dermatol; 2022 Jan; 47(1):149-151. PubMed ID: 34260095
[No Abstract] [Full Text] [Related]
56. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
[No Abstract] [Full Text] [Related]
57. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
58. Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database.
Asano H; Noguchi Y; Kimura M; Usami E; Yoshimura T
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004012
[No Abstract] [Full Text] [Related]
59. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
60. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
